Anika Therapeutics (US.ANIK)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.ANIK · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 152.1% | ↓ |
| ROE | -1.3% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.18 | ↓ |
| Gross Margin | 64.7% | ↑ |
US.ANIK (Anika Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 152.1% ↓ ROE -1.3% ↑ Cash Conversion - → D/E Ratio 0.18 ↓ Gross Margin 64.7% ↑
核心指标
US.ANIK (Anika Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 152.1% ↓ROE -1.3% ↑Cash Conversion - →D/E Ratio 0.18 ↓Gross Margin 64.7% ↑免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies